Internal Medicine, Rheumatology · Glendale, CA
NPI
1932147626
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
222 W Eulalia St, Suite 200
Glendale, CA, 91204
Phone (818) 291-4010
Groups this clinician bills Medicare through
Medicare paid, 2024
$8,244
159 services
Medicare patients, 2024
48
Average age 74
Drug cost, 2024
$1.8M
1,513 prescriptions
Company payments, 2025
$1,508
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ramesh C Kesavalu was code 99214 (office e&m - established), 69 times for 46 patients. In total Ramesh C Kesavalu billed 159 services in 10 codes, and Medicare paid $8,244.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-11-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 69 | 46 | $93.21 | $6,431 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 57 | 42 | $12.20 | $696 |
By year: 2022 $9,681 for 173 services; 2023 $7,777 for 107 services; 2024 $8,244 for 159 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ramesh C Kesavalu prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 302 prescriptions and refills. In total Ramesh C Kesavalu wrote 1,513 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 302 | 541 | 73 | $6,144 |
| Prednisone Generic | 273 | 346 | 106 | $648 |
| Hydroxychloroquine Sulfate Generic | 71 | 166 | 29 | $3,594 |
| Enbrel Sureclick Etanercept | 62 | 70 | Under 11 | $461K |
| Sulfasalazine Dr Sulfasalazine | 60 | 89 | 12 | $1,774 |
| Folic Acid Generic | 58 | 152 | 20 | $374 |
| Prolia Denosumab | 53 | 317 | 36 | $86K |
| Humira(Cf) Pen Adalimumab | 46 | 57 | Under 11 | $383K |
| Diclofenac Sodium Generic | 40 | 58 | 15 | $2,733 |
| Mycophenolate Mofetil Generic | 37 | 69 | Under 11 | $4,573 |
| Enbrel Etanercept | 36 | 36 | Under 11 | $257K |
| Azathioprine Generic | 30 | 66 | Under 11 | $587 |
| Alendronate Sodium Generic | 29 | 47 | Under 11 | $190 |
| Omeprazole Generic | 26 | 59 | Under 11 | $174 |
| Otezla Apremilast | 24 | 24 | Under 11 | $106K |
Brand drugs: 401 claims; generic drugs: 1,096 claims; opioid claims: 37.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ramesh C Kesavalu $1,508 ($1,508 in general payments such as food, travel and fees) from 11 companies. The largest payer was Abbvie Inc. with $715.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 29 | $715 |
| GlaxoSmithKline, LLC. GSK | 14 | $255 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $158 |
| Mallinckrodt Hospital Products Inc. | 4 | $107 |
| UCB, Inc. UCB.BR | 2 | $64.47 |
| Alexion Pharmaceuticals, Inc. AZN | 3 | $63.5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41.65 |
| ANI Pharmaceuticals, Inc. ANIP | 1 | $34.17 |
| Amgen Inc. AMGN | 1 | $25.6 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $23.02 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.